Search Results - "Olsen, I.C"

Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases by Semb, A.G, Ikdahl, E, Hisdal, J, Olsen, I.C, Rollefstad, S

“…Abstract Objectives Cardiovascular disease (CVD) risk calculators developed for the general population have been shown to inaccurately predict CVD events in…”
Get full text

Consequences of handling missing data for treatment response in osteoarthritis: a simulation study by Olsen, I.C, Kvien, T.K, Uhlig, T

“…Summary Objective To understand how handling of missing data influences the statistical power and bias of treatment effects in randomised controlled trials of…”
Get full text

Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases by Rollefstad, S, Ikdahl, E, Hisdal, J, Holme, I, Olsen, I.C, Smerud, K.T, Pedersen, T.R, Kvien, T.K, Semb, A.G

Get full text

The Frequency of Intrapartum Cesarean Section Use With the WHO Partograph Versus Zhang’s Guidelines in the Labor Progression Study (LAPS): A Multicenter, Cluster-randomized Controlled Trial by Bernitz, S, Dalbye, R, Zhang, J, Eggebø, T.M, Frøslie, K.F, Olsen, I.C, Blix, E, Øian, P

“…(Lancet. 2019;393:340–348)As the rate of cesarean section has been increasing worldwide, there have been efforts to encourage clinicians to avoid medically…”
Get full text

A 1‐Year Randomized, Double‐Blind, Placebo‐Controlled Study of Intravenous Ibandronate on Bone Loss Following Renal Transplantation by Smerud, K. T., Dolgos, S., Olsen, I. C., Åsberg, A., Sagedal, S., Reisæter, A. V., Midtvedt, K., Pfeffer, P., Ueland, T., Godang, K., Bollerslev, J., Hartmann, A.

“…The clinical profile of ibandronate as add‐on to calcitriol and calcium was studied in this double‐blind, placebo‐controlled trial of 129 renal transplant…”
Get full text

A large conditioned pain modulation response is not related to a large blood pressure response: A study in healthy men by Nilsen, K.B., Olsen, I.C., Solem, A.N., Matre, D.

“…Background Endogenous pain modulation has been studied with the conditioned pain modulation (CPM) paradigm with large differences in the magnitude of the CPM…”
Get full text

DOP062 Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial by Jørgensen, K.K., Olsen, I.C., Goll, G.L., Lorentzen, M., Bolstad, N., Berset, I.P., Haavardsholm, E.A., Lundin, K.E., Mørk, C., Kvien, T.K., Jahnsen, J.

Get full text